Disclosure: Long REPR
| 
	        	 We have accumulated shares of REPR - Repromed Medical Systems during the market slaughter.  This is a fast growing manufacuter of medical equipment in the USA.  Their leading product is the FREEDOM60® Syringe Infusion System.  Sales are booming and they are adding and hiring for new positions.  The P/E is very low on this stock and growth should continue.  I am looking forward to the new earnings report due around Oct 14 or so.  The stock has traded as low as 21 cents during the market downturn. 
		Disclosure: Long REPR Comments are closed. 
		
		
	 | 
	        
	            Paul SaadSenior Manager, Paul Saad and Associates, LLC Archives
		May 2020
		 Categories | 
	
		RSS Feed